The Novel T-Cell Immunotherapies Market is expected to grow at a 38.0 % CAGR during the forecast period for 2023-2031.
T-cell immunotherapy is a rapidly emerging field of oncology. T-cell therapies have come out as a promising option among the current targeted anti-cancer therapies due to their high target specificity, customization potential, ability to generate immunological memory, and minimal side effects. Some of the novel types of T-cell therapies are γδ T-cells, Tregs, activated T-cells, virus-driven T-cells, and T-cell vaccines. The gamma delta T cell therapies have shown high efficacy and specificity towards cancer cells in clinical trials compared to other conventional cancer therapies.
The primary approach of T-cells therapy is identifying the cancer-causing cells and developing a strong immune response against the cells without causing side effects. The increasing prevalence of chronic diseases is expected to propel the novel T-cell immunotherapies market growth over the forecast period. In addition, multiple collaborations between various therapy developers and research institutes/universities to develop innovative therapies support the market growth.
The increasing need for cell and gene therapies, the high prevalence of cancer, and the rising number of clinical trials will boost the market growth opportunities in the coming days. Furthermore, advanced medical technologies, a rise in the geriatric population, and a growing number of health-conscious people enhance the novel T-cell immunotherapies market development. However, the high investment cost required for therapy development, lack of standard therapy protocols, and shortage of skilled professionals restrain the market growth.
Market Segmentation
Segmentation of novel T-cell immunotherapies market includes Type of T-cell Therapy, Disease Indication, and Region. By Type of T-cell Therapy, the market can be segmented into Activated T-cells, Virus Driven T-cells, Tregs, γδ T-cells, T-cell vaccines, and NK T-cells. Based on Disease Indication, the market is segmented into Lung cancer, Breast Cancer, Cytomegalovirus Infection, Glioblastoma, Hepatocellular Carcinoma, Acute Myeloid Leukemia, Ovarian Cancer, Type 1 Diabetes Mellitus, Sarcoma, HIV infections, Pancreatic Cancer, and Others. Various types of cancer drive the growth of this market. Regionally, the novel T-cell immunotherapies market can be divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, followed by Europe, holds the maximum share of this market due to increased research and development expenditure, the presence of major market players, and the fast adoption of advanced technologies.
Competitive Landscape
Some of The Key Players in The Novel T-Cell Immunotherapies Market:
- Atara Biotherapeutics
- AlloVir
- Eureka Therapeutics
- Eutilex
- GammaDelta Therapeutics
- NexImmune
- OSE Immunotherapeutics
- TelogenBio
- WindMIL Therapeutics
- Acepodia
- Adaptate Therapeutics
- Adicet
- Cytomed Therapeutics
- Gadeta
- IN8bio
- Kiromic Biopharma
- Lava Therapeutics
- Takeda Pharmaceuticals
- TC Biopharm
- ImCheck Therapeutics
- Expression Therapeutics LLC
- Triumvira Immunologics
- PureTech Health
- PhosphoGam
- Caladrius Biosciences
- Eli Lilly and Company
- Miltenyi Biotec
- Sangamo Therapeutics (TxCell)
- Cellenkos Inc.
- Pfizer Inc.
- PolTREG S.A..
- Parvus Therapeutics
- ILTOO Pharma
- Philogen S.p.A.
- TRACT Therapeutics, Inc.
- REGiMMUNE Co, Ltd.
- Roche
- Celgene
- AHEAD THERAPEUTICS S.L.
- Other Prominent Players
The Novel T-Cell Immunotherapies Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 38.0 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of T-cell Therapy, By Disease Indication |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Atara Biotherapeutics, AlloVir, Eureka Therapeutics, Eutilex, GammaDelta Therapeutics, NexImmune, OSE Immunotherapeutics, TelogenBio, WindMIL Therapeutics, Acepodia, Adaptate Therapeutics, Adicet, Cytomed Therapeutics, Gadeta, IN8bio, Kiromic, Biopharma, Lava Therapeutics, Takeda Pharmaceuticals, TC Biopharm, ImCheck Therapeutics, Expression Therapeutics LLC, Triumvira Immunologics, PureTech Health, PhosphoGam, Caladrius Biosciences Eli Lilly and Co, Sangamo Therapeutics (TxCell), Cellenkos Inc., Pfizer Inc., PolTREG S.A.., Parvus Therapeutics, ILTOO Pharma Philogen S.p.A., TRACT Therapeutics, Inc., REGiMMUNE Co, Ltd., Roche, Celgene, AHEAD THERAPEUTICS S.L., and Others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
